Intestinal Cell News

Intestinal Cell News is an online resource that curates the latest research using intestinal cells.

Lymphatics Act as a Signaling Hub To Regulate Intestinal Stem Cell Activity

June 24, 2022

[Cell Stem Cell] Employing in vivo loss of function and lymphatic:organoid cocultures, researchers showed that crypt lymphatics maintained intestinal stem cells and inhibited their precocious differentiation.

Human 2D Crypt Model for Assaying Intestinal Stem Cell Proliferation and Differentiation

June 24, 2022

[Analytical Chemistry] A planar, self-renewing human intestinal monolayer platform based on primary adult gastrointestinal stem cells, termed the 2D crypt model, was developed to screen for the effects of various compounds on the intestinal epithelium.

Hederacoside C Ameliorates Colitis via Restoring Impaired Intestinal Barrier Through Moderating S100A9/MAPK and Neutrophil Recruitment Inactivation

June 24, 2022

[Acta Pharmacologica Sinica] The authors investigated how HSC attenuated intestinal inflammation in vivo and in vitro.

Chicken-Derived RSPO1 and WNT3 Contribute to Maintaining Longevity of Chicken Intestinal Organoid Cultures

June 24, 2022

[Scientific Reports] Based on the limited homology between mammalian and avian RSPO1, scientists expected that chicken-derived factors were required for the organoid cultures.

Cell and Chromatin Transitions in Intestinal Stem Cell Regeneration

June 24, 2022

[Genes & Development] Investigators ow that goblet, Paneth, and enteroendocrine cells arose by multilineage priming in common precursors, followed by selective access at thousands of cell-restricted cis-elements.

Spef1/CLAMP Binds Microtubules and Actin-Based Structures and Regulates Cell Migration and Epithelia Cell Polarity

June 24, 2022

[Annals of the New York Academy of Sciences] The authors outline Sperm flagella protein-1 (Spef1)/calponin homology and microtubules-associated protein (CLAMP) structure and expression in several cellular models.

Patient-Derived Organoids Identify an Apico-Basolateral Polarity Switch Associated with Survival in Colorectal Cancer

June 23, 2022

[Journal of Cell Science] Scientists reported that mucinous colorectal carcinoma tumors maintained a robust apico-basolateral polarity as they spread in the peritumoral stroma or organotypic collagen-I gels.

Single-Cell Analyses Define a Continuum of Cell State and Composition Changes in the Malignant Transformation of Polyps to Colorectal Cancer

June 22, 2022

[Nature Genetics] A large fraction of polyp and colorectal cancer (CRC) cells exhibited a stem-like phenotype, and investigators defined a continuum of epigenetic and transcriptional changes occurring in these stem-like cells as they progressed from homeostasis to CRC.

Essential Roles of TDO2 in Gastric Cancer: TDO2 Is Associated with Cancer Progression, Patient Survival, PD-L1 Expression, and Cancer Stem Cells

June 22, 2022

[Pathobiology] Tryptophan 2,3-dioxygenase (TDO2) expression was correlated with both progressive disease and clinical outcome, and its expression was an independent predictor of prognosis in GC.

ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation

June 21, 2022

[ABVC Biopharma, Inc. (Globe Newswire, Inc.)] BioKey, ABVC’s wholly owned subsidiary has entered into a Clinical Development Service Agreement with Rgene to guide three Rgene drug products: RGC-1501 for the treatment of non-small cell lung cancer, RGC-1502 for the treatment of pancreatic cancer. and RGC 1503 for the treatment of colorectal cancer patients.

G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase III Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer

June 17, 2022

[G1 Therapeutics, Inc.] G1 Therapeutics, Inc. announced that the last patient has been randomized in the Phase III clinical trial of trilaciclib for patients with metastatic colorectal cancer receiving chemotherapy.

SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn’s Disease in Adults

June 17, 2022

[AbbVie] AbbVie announced that the US FDA has approved SKYRIZI® as the first and only specific IL-23 inhibitor for the treatment of adults with moderately to severely active Crohn's disease.

Since 2015, Intestinal Cell News has been a valuable resource for keeping researchers and medical professionals updated on the latest publications, news and events in the field of gastrointestinal cell biology. Our editorial team collects and publishes the most current articles and reviews using stomach, colon, and small and large intestinal cells. We cover topics including the culturing of intestinal cells, intestinal organoids, intestinal cancers, and gastrointestinal conditions such as irritable bowel syndrome and Crohn’s disease.